Bedrosian I - Search Results

1

The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.

Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. Wingate H, et al. Among authors: bedrosian i. J Biol Chem. 2005 Apr 15;280(15):15148-57. doi: 10.1074/jbc.M409789200. Epub 2005 Feb 10. J Biol Chem. 2005. PMID: 15708847 Free article.

2

Cyclin E and survival in patients with breast cancer.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Keyomarsi K, et al. Among authors: bedrosian i. N Engl J Med. 2002 Nov 14;347(20):1566-75. doi: 10.1056/NEJMoa021153. N Engl J Med. 2002. PMID: 12432043 Free article.

3

Cyclin E is a more powerful predictor of breast cancer outcome than proliferation.

Keyomarsi K, Tucker SL, Bedrosian I. Keyomarsi K, et al. Among authors: bedrosian i. Nat Med. 2003 Feb;9(2):152. doi: 10.1038/nm0203-152. Nat Med. 2003. PMID: 12563321 No abstract available.

4

The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.

Wingate H, Bedrosian I, Akli S, Keyomarsi K. Wingate H, et al. Among authors: bedrosian i. Cell Cycle. 2003 Sep-Oct;2(5):461-6. Cell Cycle. 2003. PMID: 12963845

5

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Bedrosian I, et al. Oncogene. 2004 Apr 8;23(15):2648-57. doi: 10.1038/sj.onc.1207408. Oncogene. 2004. PMID: 15007381

6

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Eder AM, et al. Among authors: bedrosian i. Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24. doi: 10.1073/pnas.0505641102. Epub 2005 Aug 22. Proc Natl Acad Sci U S A. 2005. PMID: 16116079 Free PMC article.

7

Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.

Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC Jr. Le XF, et al. Among authors: bedrosian i. Cell Cycle. 2006 Aug;5(15):1654-61. doi: 10.4161/cc.5.15.3007. Epub 2006 Aug 1. Cell Cycle. 2006. PMID: 16861913

8

Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.

Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Bedrosian I, et al. Clin Cancer Res. 2007 Aug 15;13(16):4800-6. doi: 10.1158/1078-0432.CCR-07-0142. Clin Cancer Res. 2007. PMID: 17699858

9

Cyclin E deregulation is an early event in the development of breast cancer.

Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Shaye A, et al. Among authors: bedrosian i. Breast Cancer Res Treat. 2009 Jun;115(3):651-9. doi: 10.1007/s10549-008-0266-0. Epub 2008 Dec 24. Breast Cancer Res Treat. 2009. PMID: 19107593 Free PMC article.

10

Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis.

Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Bhardwaj A, et al. Among authors: bedrosian i. PLoS One. 2014 May 8;9(5):e97076. doi: 10.1371/journal.pone.0097076. eCollection 2014. PLoS One. 2014. PMID: 24811059 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters